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Community-based misoprostol for the prevention of post-partum haemorrhage: a narrative 
review of the evidence base, challenges and scale-up 
Achieving Sustainable Development Goal targets for 2030 will require persistent investment and creativity in 
improving access to quality health services, including skilled attendance at birth and access to emergency obstetric 
care. Community-based misoprostol has been extensively studied and recently endorsed by the WHO for the 
prevention of postpartum haemorrhage. There remains little consolidated information about experience with 
implementation and scale-up to date. This narrative review of the literature aimed to identify the political processes 
leading to WHO endorsement of misoprostol for the prevention of postpartum haemorrhage, and describe ongoing 
challenges to the uptake and scale-up at both policy and community levels. We review the peer-reviewed and grey 
literature on expansion and scale-up and present the issues central to moving forward. 
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Background  
Maternal mortality remains the most inequitable health indicator globally (World Health Organization, 2015b). 
Safe motherhood initiatives, including investments in improving access to skilled birth attendants (SBAs), emergency 
obstetric care, safe therapeutic abortion and contraception have resulted in significant reductions in maternal mortality 
globally over the last 20 years. Maternal deaths have decreased over the last quarter century  from 376 034 (95% CI: 
343 483 – 407 574) in 1990 to 292 982 (95% CI: 261 017–327 792) in 2013 (Kassebaum et al., 2014). The rate of 
decline, however, was less than half that  was needed to achieve the Millennium Development Goal (MDG) target of a 
three quarter reduction in the maternal mortality ratio between 1990 and 2015.  
 Post-partum haemorrhage (PPH) is the leading cause of maternal death worldwide (Say et al., 2014). Defined 
as bleeding in excess of 500 mL in the first 24 hours following birth (World Health Organization, 2012a), the most 
common causes of PPH include uterine atony, vaginal or cervical lacerations, retained placenta tissue, and clotting 
disorders (Arulkumaran, Regan, Papageorghiou, Monga, & Farquharson, 2011; World Health Organization, 2012a). 
After years of risk stratification studies, we have no effective way of predicting who will experience haemorrhage, 
especially in the absence of an SBA caring for women during labour and the post-partum period (Devine, 2009; Edhi, 
Aslam, Naqvi, & Hashmi, 2013; El-Refaey & Rodeck, 2003; Potts & Hemmerling, 2006). This evidence forms the 
rationale for the primary prevention of PPH for every woman, immediately post-partum. Thirty years of global efforts 
have focused on training SBAs and standardizing the active management of the third stage of labour (AMTSL), said to 
be the single most effective method to prevent PPH at birth (Devine, 2009). Active Management of Third Stage of 
Labour (AMTSL) is by definition delivered by an SBA, and when administered correctly, halves the risk of PPH 




Uterotonics are arguably the most essential component of AMTSL (Gülmezoglu et al., 2012).  Oxytocin  
remains the gold standard uterotonic of choice (World Health Organization, 2012a). Every major international 
oversight body recommends intravenous or intramuscular oxytocin for the prevention of PPH, and a tablet-form 
uterotonic, misoprostol (600 mcg oral), if and when oxytocin is not available (World Health Organization, 2012a). 
Oxytocin is heat labile and administered via injection, and thus often inaccessible to women giving birth outside health 
facilities (Raghavan, Abbas, & Winikoff, 2012; World Health Organization, 2012a). In practice, even when SBAs are 
equipped with oxytocin for home and facility births, it is often stored incorrectly and thus less efficacious (Torloni, 
Freitas, Kartoglu, Gulmezoglu, & Widmerc, 2016; Wilson et al., 2012).  
 
Recent efforts have focused on the use of misoprostol to reach women who deliver at home without a SBA. 
Misoprostol is a synthetic prostaglandin E1 originally developed for the prevention and treatment of gastric ulcers in 
1985 (Garris & Kirkwood, 1989). Compared to oxytocin, misoprostol does not require refrigeration, and can be 
administered orally, sublingually, rectally and vaginally (Wise & Clark, 2008). Giving birth with an SBA is still 
recommended as the most essential step to decrease maternal mortality, and full coverage of facility births remains the 
ultimate goal (Murthy & Smith, 2009).  Until every woman has access to an SBA, however, experts argue that the 
community distribution of misoprostol is a scalable and relatively safe intervention to reduce PPH (Oladapo, 2012; 
Prata, N. et al., 2011b; Smith, J. M., Gubin, Holston, Fullerton, & Prata, 2013). The WHO includes misoprostol for the 
prevention of PPH on the Essential Medicine List and community-based distribution (CBD), but has yet to recommend 
the advance distribution of misoprostol for self-administration (ADMSA) (World Health Organization, 2012a).   
This narrative review aims to explore the context for on-going tensions between policy and practice 
surrounding the community-based distribution of misoprostol for PPH in low-income settings. advance We present a 
broad literature review and update the existing pilot studies on community-based distribution of misoprostol. We then 
outline the existing literature on expansion and  scale-up to help understand why efforts to increase  the availability of 





A narrative review of both the qualitative and quantitative data was chosen over a systematic review to include both 
experimental and non-experimental descriptive studies (Whittemore & Knafl, 2005) as well as grey literature with 
narrative descriptions of programme challenges (Slavin, 1995). An initial set of papers were identified using the 
literature review strategy below, including “scale” and “scale-up” to broaden the scope of previous reviews. We 
conducted forward snowballing from the references of papers that met inclusion criteria.  Grey literature searches from 
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UN agencies, governmental and non-government organisations websites and reports were included. Ethical clearance 
was obtained from the Human Research Ethics Committee at Charles Darwin University, Australia (HREC 2015-
2445). 
Literature review strategy 
This review was conducted using four databases: Medline, Cochrane Review Library, CINAHL and ProQuest 
Dissertation & Theses Database. The search strategy included a combination of terms, including ‘misoprostol’; ‘post-
partum haemorrhage’ (and variations i.e. ‘postpartum haemorrhage’, ‘post-partum hemorrhage’) ‘community-based 
maternal’; ‘maternal’; ‘maternal health interventions’; ‘maternal mortality’; ‘low-income setting’; ‘developing 
country’; ‘resource-poor setting’; ‘traditional birth attendant’; ‘scale’ and ‘scale-up’.  
Inclusion and exclusion criteria 
Dates were not restricted up until March 1st, 2016. Only English articles or those with an English translation were 
included. KH screened the literature for relevance to programmes using all modes of administration and doses of 
misoprostol for the prevention of PPH. Articles were excluded if the research took place in high-income countries, 
defined by a GNI per capita higher than 12 476 USD (World Bank, 2016). Articles were also excluded if conducted 
exclusively in clinical settings without a community component and if not specific to misoprostol; for example, TBA 
programmes that did not use misoprostol, or misoprostol for an indication other than the prevention of PPH, including 
abortion or induction of labour.  
Results 
A total of 249 articles were retrieved and screened from our search strategy. Of these, 135 full text articles were 
assessed for eligibility. See Figure 1. In total, 84 articles were eligible. Findings were organized into four  major 
categories: evidence for the use of misoprostol in community settings; political momentum for the CBD of 
misoprostol, challenges to uptake in community settings; and the expansion and scale-up of CBD misoprostol. .   
A total of 24 articles were included in the synthesis of CBD pilot studies. Many of these trials published before 
2013 were detailed in the Smith et al. (2013) review of global implementation of misoprostol. The seven studies 
published after the 2013 review are outlined in Table 1.We identified nine studies of “scale”, defined for the purposes 
of this review as deliberate post-pilot efforts to expand CBD programs or include CBD of misoprostol in a national 
policy or operational plan. These are outlined in Table 2.  




Evidence for Community-based Distribution of Misoprostol for the prevention of PPH 
As early as 2002, a number of countries introduced pilot studies to assess the feasibility of distribution of misoprostol 
through CHWs or antenatal care (ANC) visits, with promising results (Derman et al., 2006; Mobeen et al., 2011; Prata, 
N, Mbaruku, Campbell, Potts, & Vahidnia, 2005; Rajbhandari et al., 2010; Sanghvi et al., 2010; Sanghvi, 
Wiknjosastro, Chanpong, Fishel, & Ahmed, 2004). Findings from the seven pilot studies published after the Smith et 
al. review (2013), outlined in Table 1, drew similar conclusions to previous studies. Most trials concluded that women 
who used misoprostol self-reported significantly less heavy bleeding than those who did not receive uterotonics; where 
bleeding was objectively measured, the rate of PPH was significantly lower compared to placebo or no uterotonic. 
Most studies also measured significantly fewer bleeding-related referrals.   The vast majority of women enrolled were 
able to correctly administer the medicine themselves or with the assistance of a community-based worker. Studies were 
often hosted in areas with very poor access to assisted deliveries, and misoprostol invariably increased uterotonic 
coverage - from 11.6% to 74.2% in 1 district of Nepal, for example (Rajbhandari et al., 2010). Community-based 
distribution of misoprostol nearly doubled the coverage rate versus distribution through health workers or ANC visits; 
in South Sudan, a 2014 study showed an even more dramatic difference in coverage when the drug is distributed via 
ANC versus home visits (17.2% versus 82.8%) (Smith, J.M., Baawo, S.D., et al., 2014) . Low coverage achieved in the 
Liberian study (24% of home births) was attributed to reliance on skilled heath providers to counsel and distribute 
misoprostol.  Several studies also documented that TBA and self-administered misoprostol programmes can work to 
bolster access to SBAs (Haver, Ansari, Zainullah, Kim, & Tappis, 2016; Prata, N. et al., 2011b). Acceptability was 
universally high: 87 - 99% of women would recommend misoprostol, and 54.6% - 95% were willing to pay. Several 
reviews have now examined the evidence for CBD of misoprostol for prevention of PPH, with similar 
conclusions(Flandermeyer, Stanton, & Armbruster, 2010; Smith, H. J. et al., 2015; Smith, J. M. et al., 2013). Two 
systematic reviews limited to randomized controlled trials (RCTs) of misoprostol in community settings were 
inconclusive, and called for large RCTs to confirm the safety and effectiveness of both CBD and ADMSA (Hundley et 





Political momentum for the Community-based Distribution of Misoprostol  
The grey literature revealed a number of key political events that enabled misoprostol to be used in community 
settings for PPH. We present a chronological timeline in Figure 2. 
The Derman et al. (2006) study was published amid growing evidence that misoprostol could be self-
administered where SBAs and oxytocin are unavailable (World Health Organization, 2007a). In response, the WHO 
convened a technical consultation on the prevention of PPH in October of 2006.  They concluded that oxytocin should 
remain the uterotonic of choice for the prevention of PPH and that there was insufficient evidence to recommend 
misoprostol given safety concerns and fear of misuse (Mathai, Gulmezoglu, & Hill, 2007; World Health Organization, 
2007b). In 2007, WHO recommendations evolved somewhat to include misoprostol for PPH prevention in the absence 
of oxytocin: ‘In the absence of active management of the third stage of labour, an uterotonic drug (oxytocin or 
misoprostol) should be offered by a health worker trained in its use for prevention of PPH’ (World Health 
Organization, 2007b, p. 14). The report did not address use in home births.  
 
In 2009, the WHO released a formal statement on the use of misoprostol for prevention and treatment of PPH 
that explained why misoprostol was not on the WHO Essential Medicines List. They cited inconsistency of the studies 
comparing misoprostol to placebo; the significant risk of side effects; and concerns about the risk of maternal death 
given the potential for misuse (World Health Organization, 2009). 
 
In spite of the lack of WHO support and approval, several countries had already taken steps to initiate the use 
of misoprostol for the prevention of PPH. In January 2006, Nigeria became the first country in the world to register 
misoprostol for prevention and treatment of PPH (Jadesimi & Okonofua, 2006). Ethiopia and Tanzania followed later 
that year, including misoprostol for PPH prevention on their respective National Essential Medicines List (Campbell & 
Holden, 2006).  
 
With growing evidence and advocacy by maternal health experts, misoprostol was added to the WHO’s 
Essential Medicines List in 2011 ‘for prevention of post-partum hemorrhage where oxytocin is not available or cannot 
be safely used’ (World Health Organization, 2011, p. 29). In 2012, the WHO formally endorsed the administration of 
misoprostol for PPH prevention: ‘In settings where SBAs are not present and oxytocin is unavailable, the 
administration of misoprostol (600 µg PO) by community health care workers and lay health workers is recommended 
for the prevention of PPH’ (World Health Organization, 2012a, p. 5). In the same year, the WHO explicitly recognised 
that CHWs could contribute significantly to reduce PPH through the administration of misoprostol after home births 
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(World Health Organization, 2012b). This 2012 endorsement is considered a major turning point in garnering 
international support to use misoprostol for prevention of PPH (Karanja, Muganyizi, Rwamushaija, Hodoglugil, & 
Holm, 2013). The WHO upheld the recommendation for use of misoprostol for prevention of PPH in 2015 (World 
Health Organization, 2015a).  
 
The WHO has yet to recommend the ADMSA. They cite the need for further research on safety, efficacy and 
coverage (World Health Organization, 2012a). Advance distribution achieves significantly higher uterotonic coverage 
at birth, and advocates see the lack of WHO endorsement of ADMSA as a major barrier to uptake (Smith, J.M., 
Baawo, S.D., et al., 2014; Smith, J. M. et al., 2013; Wells, E. et al., 2014).  
FIGURE 2 HERE 
 
 
Challenges to implementing misoprostol programmes in community settings 
The literature is dotted with potential challenges to  using misoprostol as an effective, alternative uterotonic in the 
absence of oxytocin, despite WHO endorsement (Chu, Brhlikova, & Pollock, 2012; Hundley et al., 2013; Oladapo, 
2012; Starrs & Winikoff, 2012). The reasons for this are multifold: lack of direct evidence for reducing maternal 
mortality; safety and side effects; fear of misuse; reluctance to invest in CHWs; and detraction from facility-based 
births. One review specifically examined the barriers to implementation of community-based misoprostol programmes 
for prevention of PPH, and identified similar results (Smith, H. J. et al., 2015). 
Lack of evidence for impact on maternal mortality 
Misoprostol for prevention of PPH lacks direct evidence in reducing maternal deaths (Chu et al., 2012; Hofmeyr, 
Gulmezoglu, Novikova, & Lawrie, 2013; Hundley et al., 2013). RCTs comparing misoprostol to placebo in community 
distributions noted significant reductions in the incidence of PPH (Derman et al., 2006; Mobeen et al., 2011). 
However, some argue this is insufficient evidence for real reductions in maternal mortality (Chu et al., 2012; Oladapo, 
2012).  
 
Direct evidence on maternal mortality reduction is exceedingly difficult to measure given maternal mortality is 
a relatively rare event (Hofmeyr et al., 2009). A 2012 Cochrane systematic review assessed the effectiveness and safety 
of advance misoprostol distribution for PPH prevention and treatment in non-facility births (Oladapo, Fawole, Blum, & 
Abalos, 2012). Due to design flaws, no studies met the inclusion criteria. The lack of evidence regarding the direct 
impact on the reduction of maternal mortality remains a key concern for some policy and health experts.  
Safety and side effects 
The safety and side effect profile of misoprostol continues to be cited as a concern. Shivering, fever, nausea and 
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diarrhea are commonly reported side effects (Gülmezoglu et al., 2001; Oladapo, 2012). In several studies, the 
incidence of side effects has been significantly higher in misoprostol groups (Mobeen et al., 2011; Patted et al., 2009; 
Weeks et al., 2015). In a pilot study in Afghanistan, however, reported side effects were lower in the intervention 
group (Sanghvi et al., 2010). Many argue that the side effects are well understood, and can be easily managed 
(Grossman, Graves, Rwamushaija, & Park, 2010; Oladapo, 2012). 
 
Uterine rupture is the most serious risk associated with misoprostol if taken before birth, which is true for any 
uterotonic (Hofmeyr, Say, & Gülmezoglu, 2005). A Cochrane review found no significant difference in maternal 
deaths or severe morbidity with misoprostol versus other uterotonics for the prevention or treatment of PPH (Hofmeyr 
et al., 2013).  
Fear of misuse 
Another challenge to wide-scale acceptance of misoprostol for PPH prevention is potential misuse. AHowever, 
available evidence suggests that both misuse and diversion is uncommon. For example, mistimed administration of 
misoprostol in CBD  programmes were reported as minimal (0.6%) in a global mapping study (Grenier, 2013). In a 
Ugandan study of 700 women, only two women had taken either misoprostol or placebo tablets early while the fetus 
was still in utero (Weeks et al., 2015). Similarly, in Liberia, only three of 265 women took misoprostol prior to giving 
birth (Smith, J.M., Baawo, S.D., et al., 2014). No adverse outcomes were reported in either study. A doctoral thesis on 
misuse of uterotonics in Southern Nepal found that over 90% of oral uterotonics were administered correctly according 
to FIGO guidelines (Connor, 2013).  
 
Concern that misoprostol will be used for elective abortion is an ongoing concern. (Bazzano, Jones, & Ngo, 
2014; Coeytaux et al., 2014; Geressu, Tibebu, Coeytaux, & Wells, 2014). When misoprostol is used alone, it is 85% 
effective in termination of pregnancy under 12 weeks (International Women's Health Coalition & Gynuity Health 
Projects, 2010). Several governments in countries where elective abortion is illegal have restricted access to 
misoprostol for fear it will be used for termination of pregnancies (Coeytaux & Wells, 2011; Kulczycki, 2011; Kumar, 
2012). Another fear is that CHWs will use misoprostol inappropriately to induce labour (Grenier, 2013; Smith, H. J. et 
al., 2015). There is, however, no evidence to suggest that misoprostol distributed for the purpose of the prevention of 
PPH is being diverted for labour induction or pregnancy termination (Grenier, 2013; Starrs & Winikoff, 2012). The 
Hundley et al. (2013) systematic review concluded that while most women take the drug at the appropriate time, more 
research is needed to inform safety protocols and communication strategies. 
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Reluctance to invest in CHWs  
After  major investment in TBA training programmes in the 1970s and 80s, a meta-analysis revealed minimal impact 
on maternal mortality (Sibley & Ann Sipe, 2004). This led to the current-day reluctance from policy-makers to invest 
in the training of less qualified CHWs and TBAs (Prata, N. et al., 2011a). Many believe resources should be focused 
on training and retaining SBAs, as emphasized in the MDGs (Ronsmans, Campbell, Mcdermott, & Koblinsky, 2002). 
Others argue that TBAs were never armed with appropriate training and technology or reliable referral mechanisms, 
and misoprostol may now provide a useful tool (Karoshi & Keith, 2009; Prata, N. et al., 2011b). In combination with 
evidence for other low-cost interventions such as birth kits and chlorohexidine, there may now be a real opportunity for 
TBAs to reduce maternal and newborn mortality (Prata, N. et al., 2011b; Prata, Ndola et al., 2012). Importantly, CBD 
resulted in nearly double the coverage of misoprostol compared to distribution through health workers or ANC visits 
(Smith, J. M. et al., 2013).  
Detraction from a facility-birth strategy 
The goal of universal coverage of facility-based births lies at the core of global maternal mortality reduction efforts 
(Bazzano et al., 2014; United Nations, 2015). This must be accompanied by adequate numbers of SBAs, equipment 
and supplies, and surgical care (Murthy & Smith, 2009). Governments and policy makers cite concern that advance 
distribution of misoprostol will detract from facility-based birth strategies (Collins, Mmari, Mullany, Gruber, & 
Favero, 2016; Geressu et al., 2014; Weeks et al., 2015). This has not been borne out in Ghana (Geller et al., 2014) 
Indonesia (Sanghvi et al., 2004), Nepal (Khanal et al., 2012), Liberia (Smith, J.M., Baawo, S.D., et al., 2014) or 
Afghanistan (Sanghvi et al., 2010), where CBD misoprostol programmes found an increase in coverage of SBA and 
facility-based births. However, this link was not found to be directly causal and other factors such as an increase in 
SBA or infrastructure investment may have also influenced outcomes.  In Ethiopia, place of birth (health facility or 
home) was not associated with women who received misoprostol during pregnancy (Sibley et al., 2014).  
 
Scale-up of community-based distribution of misoprostol 
The WHO defines scale up as the following: “…deliberate efforts to increase the impact of health service 
innovations successfully tested in pilot or experimental projects so as to benefit more people and to foster policy and 
programme development on a lasting basis” (Simmons, Fajans, & Ghiron, 2007, p. viii). Scale-up of advance 
distribution of misoprostol for PPH requires supportive policies and a permissive environment to back the intervention 
(Grenier, 2013; Karanja et al., 2013). For misoprostol, implementation is also complex, and demands support of 
national governments to develop national guidelines and policies, including the essential medicines list, procure and 
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distribute the drug, and not least, train health staff and community workers (Robinson, Kapungu, Carnahan, & Geller, 
2014).  
Despite explicit commitments from governments, the act of ‘going to scale’ with community-based distribution and 
self-administration of misoprostol has been both slow and challenging (Karanja et al., 2013; Oladapo, 2012). Delayed 
2012 endorsement from the WHO for distribution by CHWs, coupled with the challenges outlined above, may limit 
government buy-in to scale programmes (Smith, H. J. et al., 2015).  
 
From 2006 to 2012, there were several major developments of international programmes using misoprostol for 
the prevention of PPH: 15 programmes were initiated in 11 countries (Coeytaux & Wells, 2011; Smith, J. M. et al., 
2013). As of 2013, more than 30 countries had registered misoprostol for PPH prevention (Grenier, 2013). In 
2014,Venture Strategies Innovations developed a map of countries that have registered misoprostol by indication 
which depicts slightly different results (Venture Strategies Innovations, 2014).  A 2012 survey found that 16 of 37 
study countries had piloted ADMSA (Smith, J. M., Currie, Cannon, Armbruster, & Perri, 2014). By 2014, however, 
only five of these 16 countries - Afghanistan, Bangladesh, Ethiopia, Nepal and Nigeria - were actively scaling for 
wider distribution (Smith, J. M. et al., 2014).  
Progress on Scale-up 
At the time of writing, documented progress to expand advance distribution of misoprostol for PPH was available from 
Afghanistan, Bangladesh, Ethiopia, Ghana, Nepal, Nigeria and South Sudan. Published evaluations of scale-up efforts 
are limited, and only nine evaluations were retrieved (see Table 2). Bangladesh and Nepal are the only countries which 
have documented persistent efforts to move to scale. Three evaluations conducted by the Public Health Institute 
revealed varying progress on expansion of pilot studies in Ghana and Nigeria, while the project has been discontinued 
in Ethiopia (Wells, E. et al., 2014).  
 
In Afghanistan, the Ministry of Public Health (MoPH) requested the support to conduct a pre and post 
intervention evaluation of the expansion of advance distribution of misoprostol for PPH (Haver et al., 2016). Advance 
distribution of misoprostol in the community significantly increased uterotonic coverage, especially in rural and remote 
areas (Haver et al., 2016). Community involvement, including religious leaders and CHWs, in the process of 
introducing the programme was seen as paramount to its success (Cristy, 2013). Based on the findings, the MoPH 
included expansion of misoprostol as a priority in the 2012-2016 Reproductive Health Strategy, and the authors 




In Bangladesh, the ‘National Scale-up Plan’ was approved in 2010 and expansion began in 2011 in 4 districts 
with a plan to expand nationally (Family Care International, 2012). Operations research on scale-up in 29 sub-districts 
in 6 provinces in Bangladesh found misoprostol distributed through clean birthing kits was effective, feasible and safe, 
and achieved 60% coverage of uterotonics for women who gave birth at home (Quaiyum, Holston, Hossain, Bell, & 
Prata, 2011). Authors recommend extending distribution beyond ANC and using other networks of trained TBAs to 
increase coverage and scale-up.  
 
The Ethiopian Ministry of Health included misoprostol for the prevention of PPH within the 2011-2015 
strategy to reduce maternal and newborn morbidity and mortality (Geressu et al., 2014). The strategy provided 
guidance for Health Extension Workers to distribute misoprostol to prevent PPH at home births. Important differences 
in misoprostol coverage and interpretation of national misoprostol policy were  revealed between two regions of 
Ethiopia (95% coverage in Oromiya Region versus 25% in Amhara Region), likely due to one health authority which 
permitted wider distribution through skilled providers, health extension workers and community-based volunteers 
(Sibley et al., 2014; Spangler, Gobezayehu, Getachew, & Sibley, 2014). The authors recommend implementing a 
variety of distribution methods to assist in increasing reach (ANC, SBA, TBA and CBW) (Sibley et al., 2014). A 2014 
process evaluation identified that decision makers fear induced abortion and detraction from facility-based births, 
which have stalled efforts to continue  scale-up (Geressu et al., 2014).  
 
In Ghana, a process evaluation of scale-up found high rates of adherence and acceptance of misoprostol within 
the community (Azasi, Coeytaux, & Wells, 2014). Misoprostol is integrated into the national health system’s 
continuum of care model and distributed in advance at ANC to women who are in the third trimester. Women are 
provided with information about how to use the medication appropriately; emphasis is on birthing at a health facility 
where possible. A community outreach component has CHWs and TBAs conducting home visits to provide further 
information to women about safe delivery and encourage ANC attendance to receive misoprostol.  In 2014, the 
National PPH Strategy designated scale-up of misoprostol to 30% of the country in regions with the highest burden of 
home births. Ghana was in a good position to scale-up, yet expansion was proceeding slowly due to limited financial 
resources for training and procurement as well as the underlying concern that misoprostol may be used for abortion 
(Azasi et al., 2014). The authors note that because the project was within a Millennium Development Village with 
adequate infrastructure, human resources and available services, it may be challenging to integrate the model into the 
Ghana Health Service.  
 
The Government of Nepal approved a staged national scale-up of misoprostol at home births in 2010 
(Government of Nepal Ministry of Health and Population, New Era, & Gynuity Health Projects, 2014). By 2012, 
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misoprostol reached 22 districts with assistance from international donors, and by 2013, the programme had rapidly 
expanded to cover 31 of 75 districts (Government of Nepal Ministry of Health and Population et al., 2014). Evaluation 
revealed a number of challenges, including poor coverage at 15%, stock-outs at least once in the previous 12 months of 
the survey were found in a third of health facilities and difficulties with retrieval of distributed but unused tablets. Low 
uptake of misoprostol for women who received but did not consume was attributed to higher rates of institutional 
births. The authors recommend a strategic focus on remote areas with frequent home births and re-emphasis on 
universal distribution by CHWs void of perceptions of where they believe the birth will take place (Government of 
Nepal Ministry of Health and Population et al., 2014).  
 
In Nigeria, the programme model relies on TBAs and CHWs to distribute misoprostol within clean birth kits 
(Otive-Igbuzor, Danmusa, Potts, Coeytaux, & Wells, 2014). One project has expanded to two districts; further 
expansion may be limited by the need to create new community health positions given the lack of existing structures 
(Otive-Igbuzor et al., 2014). The Ministry of Health has also been reluctant to allow CHWs and TBAs to distribute the 
drug as they are not considered ‘trained community agents’ (Wells, E. et al., 2014, p.14). 
 
South Sudan has been implementing advance distribution of misoprostol for PPH prevention since 2012 as a 
component of the national PPH  programme (Smith, J.M., Alexander, D., et al., 2014). Advance distribution by home 
health promoters was found to be safe, feasible and effective with high uterotonic coverage (Smith, J.M., Alexander, 
D., et al., 2014). Almost 10, 000 women received uterotonics immediately after birth across the two states from 2013 - 
2015, a vast improvement from almost no uterotonic coverage prior to launch (Jhpiego, 2015). While the  programme 
had plans to expand to three additional counties (Jhpiego, 2015) it has now ceased due to funding cuts in 2016.  
 
TABLE 2 HERE 
A number of countries are in the early phases of scale-up, with no published reports at the time of writing. In 
Mozambique, for example, the 2013-2015 Strategy for the Prevention of PPH in the Community includes distribution 
of misoprostol in the community in 35 districts (Libombo et al., 2013). Similarly, India, Madagascar and Pakistan have 
adopted policies or guidance surrounding use of misoprostol for PPH (Larson, Raney, & Ricca, 2014; Sarwar, 
Cutherell, Noor, Naureen, & Norman, 2015). Obstacles to implementation persist. In Madagascar, the drug has not yet 






This review highlights the evidence and historical timeline for community-based misoprostol for the prevention of 
PPH, the challenges surrounding its use, and minimal progress on scale-up to date. The scientific literature and 
operations research remains incomplete, but the available literature suggests that in practice, misoprostol approaches 
the safety and efficacy of other uterotonics. CBD  programmes have consistently demonstrated that CHWs can 
distribute misoprostol, and women can take the medication appropriately. WHO recommends misoprostol as a safe, 
affordable and feasible strategy for women who give birth at home and included it on the Essential Medicines List; 
however, the WHO fell short of endorsing advance community-based distribution. Policy makers in several countries 
have been reluctant to make it a national priority, in part because of hesitant WHO support and lack of RCTs. Ongoing 
concerns about safety, efficacy, and aptitude of CHWs plague the history of misoprostol; notably, concerns about 
diversion and misuse for both induction of labour and induced abortion underpin much of the stagnation in expanding 
national programmes, including in Ethiopia (Geressu et al., 2014; Spangler et al., 2014).  
 
Strategies to overcome fear of misuse have been trialed, including branding the tablets as ‘safer after-birth’ 
(Vallely et al., 2016 p.2) and establishing strict controls that monitor distribution and retrieval of unused pills (Azasi et 
al., 2014; Geller et al., 2014; Grenier, 2013; Vallely et al., 2016; Wells, E. et al., 2014). Strict controls applied in a 
pilot, however, may not be feasible or sustainable for scale-up due to the heavy administrative burden; health staff and 
CHWs can encourage women to return unused doses of misoprostol to the health facility without tracking each pill 
(Azasi et al., 2014). The politics of who can distribute medicines also threatens the expansion of advance distribution 
of misoprostol in Nigeria and Ethiopia despite a successful pilot phase. Disquietude about relinquishing power to 
community-based workers is a recurrent theme through the history of CHW engagement (Perry & Zulliger, 2012). The 
advance distribution of misoprostol through antenatal care visits bypasses CHWs altogether, especially where networks 
are weak; the corollary to that is clear evidence that community based distribution can double coverage (Smith, J. M. et 
al., 2013).  
We describe several efforts to expand community distribution of misoprostol in Afghanistan, Bangladesh, 
Ethiopia, Ghana, Nepal, Nigeria and South Sudan. They share a combination of successful pilot studies, central 
leadership, integration into national reproductive and maternal health strategies, and existing cadres of CHWs or 
TBAs. Several country examples highlight the need for strategic investments including infrastructure, supplies, 
equipment and training, combined with careful results-based monitoring are needed to sustain misoprostol programmes 
and reach those most in need (Freedman et al., 2007).   Documentation of programme expansion is weak, and is not 
always congruent with what is happening in practice; for example, colleagues have reported that programmes are 
expanding in Pakistan and Tanzania, but no formal documentation was found in this review. Even among countries 
like Ethiopia and South Sudan with successful pilots, explicit government commitment and integration within national 
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policy and strategies, few have been able to operationalize national programmes. Many of the challenges moving from 
the pilot stage to policy and widespread implementation are expected in scaling interventions (Smith, J.M., De Graft-
Johnson, Zyaee, Ricca, & Fullerton, 2015; Wells, E. et al., 2014). Governments may benefit from assistance to develop 
national guidelines, drug monitoring and distribution, coverage and monitoring plans, inclusion on the national 
essential medicines list and training staff and CHWs (Robinson et al., 2014). 
 
 It remains unclear to what extent the challenges highlighted in the literature have deterred scale-up of 
community-based or advance distribution of misoprostol for PPH. USAID’s Maternal and Child Health Program is 
currently undertaking the study of scale-up of advance distribution of misoprostol for self-administration (ADMSA) to 
better understand the factors that facilitate and restrict successful scale-up. Implementation science could assist other 
countries and organizations who are planning the scale-up of ADMSA and inform key strategies to avoid delays 
(Grenier, 2015).   
 
Decision makers are likely sensitive to the wording used by WHO in the PPH guidelines, highlighted by the 
controversy in Nigeria and Ethiopia of what constituted a “community health care  worker or a lay health care worker” 
(World Health Organization, 2012a, p. 5).  In 2010, the WHO clarified its position stating “While WHO does not 
condemn the community distribution of misoprostol during pregnancy, WHO does not recommend such practice 
because its potential benefits and harms are currently unknown and recommends proper research to evaluate its role in 
reducing maternal deaths” (World Health Organization, 2010, p.1). The brief concludes by stating that WHO has a 
cautious position regarding the advance distribution of misoprostol during pregnancy and recommends further rigorous 
research which will be reviewed critically and used to update recommendations to Member States as appropriate 
(World Health Organization, 2010).  
 
 Lack of clear endorsement of the advance distribution is related to trust in both the CHW and women 
themselves – not to sell, not to misuse, abort or induce or accelerate labour and ultimately to take misoprostol at the 
right time (Wells, Elisa et al., 2016). The WHO argues for further research on safety, efficacy and coverage before they 
will support CBD (World Health Organization, 2012a).  This review and that of Smith et al (2013) negates many of 
these concerns.  The behavioural outcomes of interest have been successfully studied in operations research studies and 
are difficult to elucidate in an RCT (Geller et al., 2014; Potts & Hemmerling, 2006).   Further research is required to 
better understand the factors that drive national scale-up and institutionalization, and to inform WHO policy 




This review supports the rationale for providing alternative uterotonics to women with little choice but to deliver at 
home. We conclude that it is a relatively safe, affordable and simple method to prevent PPH for women unable to 
access health facilities or an SBA. Experience to date suggests that we can simultaneously bolster the coverage and 
quality of skilled attendance at birth and strengthen health systems to bring advance distribution of misoprostol to 
scale.  
A number of challenges to advancing the use of misoprostol for PPH prevention were highlighted; their 
influence on decision makers remains poorly understood.  Expansion and scale-up of community distribution of 
misoprostol is ongoing in several countries; however coverage remains incongruent with the large number of pilot 
studies and evidence in favour of its use. Operations research at the country-level is urgently needed to inform 
evidence-based decision-making and programme planning, and to understand the critical pathways that allowed 
decision makers to progress past the pilot phase to scale an evidence-based maternal health intervention.  
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Table 1. Studies on the use of misoprostol for prevention of PPH at home births since Smith et al.’s 2013 Global Review (7) 
 
  
Year (s) of 
distribution  
Country  Distribution and 
administration method 
Dose Design No women enrolled No women who took 
misoprostol at home birth 
January 2011 
June 2012 
Ghana (Geller et 
al., 2014) 
ANC + self-administered 600 mcg PO Pilot study, 1 district 654  
18 communities intervention 
(Group A); 12 communities 







Research assistants or at 
health facility + self-
administered 




et al., 2015) 
ANC + self-administered 600 mcg PO Randomised, double-blind, placebo-
controlled trial, 1 district 





Rwanda (Dao B 
et al., 2015) 
CHW distributed + 
administered 
600 mcg PO Longitudinal observational study, 4 districts 4074; no control group 







Alexander, D., et 
al., 2014) 
ANC and by CHW + self-
administered 
600 mcg PO Observational, 1 county 787; no control group 527  
December 2012- 
June 2013 
Liberia (Smith, J. 
et al., 2014) 
ANC (78%) + self 
administered or by an SBA 
(21.8%) 




October 2014  
Papua New 
Guinea (Vallely 
et al., 2016) 
ANC as part of a clean 
birthing kit + self-
administered  




Table 2: Studies assessing scale-up of misoprostol for prevention of PPH 
Country Study Design  Coverage Mode of Distribution Key dates:  
Afghanistan (Haver et al., 2016) Before & after evaluation  
 
20 Districts in 5 
provinces 
CHW - self-administration  • 2005-2007 Pilot study  
• January 2011 - April 2012 Intervention 
• November-December 2010 and March-April 2012 Pre and post data 
collection 
Bangladesh (Quaiyum et al., 2011) Large scale operations research; 
118 500 women enrolled  
 
29 Sub-districts 
in 6 districts 
ANC or TBA via safe birthing 
kit, self-administration or TBA 
• 2007 Misoprostol Use Policy and roll-out plan  
• May 2009-September 2010 pilot  
• May 2009-2010 ongoing monitoring 
Ethiopia (Sibley et al., 2014).  
 
Before & after evaluation  2 Regions (3 
woredas in each)  
 
SBA, TBA & Health Extension 
Workers, Oromiya Region  
SBA & Health Extension 
Workers, Amhara Region 
• July 2005- July 2007 pilot  
• May 2012-June 2012 Evaluation 
Ethiopia (Spangler et al., 2014) Qualitative interviews with 
health officials 
2 Regions SBA, TBA & Health Extension 
Workers in Oromiya Region  
Amhara Region SBA & Health 
Extension Workers 
• April-August 2012 Evaluation 
Ethiopia (Geressu et al., 2014) Process evaluation 1 Region (2 
Administrative 
Zones) 
CHW: Lay youth mentors and 
Community Health Extension 
Workers administered  
• 2010 misoprostol registered for PPH  
• 2010 August-December distribution  
• 2014 June – November Evaluation  
Ghana (Azasi et al., 2014) Process evaluation 1 project area in 
1 district 
ANC (7 months+) -self 
administration 
• 2008- 2012 pilot implementation , distribution ongoing 
• 2010 misoprostol on National Essential Medicines List 
• June-November 2014 Evaluation 
Nigeria (Otive-Igbuzor et al., 2014) Process evaluation 
 
 
2 States, 11 areas 
& 2 communities  
CHWs: TBAs via clean birthing 
kits prior to or at birth & drug 
keepers for self-administration or 
to TBA  
• 2009 pilot (Ejembi & Prata, 2010; Prata, N., Ejembi, Fraser, Shittu, & 
Minkler, 2012) 
• 2010 scale-up in 2 states commenced 
• June-November 2014 Evaluation 
Nepal (Government of Nepal Ministry of Health 
and Population et al., 2014) 




9 Districts  CHWs (8 months+) - self-
administration 
• January 2006- June 2008 pilot  
• 2010 national scale-up approved 
• 2013 Evaluation 
South Sudan (Smith, J.M., Alexander, D., et al., 
2014) 
Observational 1 County ANC & CHW-self-
administration 
• October 2012 -March 2013 Evaluation 
 
24 
 
